Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Congenital heart disease (CHD) is the most common type of birth defect, but its underlying molecular mechanisms remain unidentified. Previous studies determined that Homo sapiens
LYR motif containing 1
(
LYRM1
) is a novel nucleoprotein expressed at the highest level in adipose tissue and in high levels in heart tissue. The
LYRM1
gene may play an important role in the development of the human heart. This study was designed to identify the biological characteristics of the
LYRM1
gene in heart development. On the basis of expression-specific differentiation markers identified with quantitative real-time RT-PCR and the morphology of
LYRM1
-overexpressing cells during differentiation, ectopic expression was not found to significantly affect differentiation of P19 cells into cardiomyocytes. MTT assays and cell cycle analysis showed that
LYRM1
dramatically increases the proliferation of P19 cells. Furthermore, data from annexin V-FITC binding and
caspase-3
activity revealed that
LYRM1
can inhibit the apoptosis of P19 cells. Our data suggest that
LYRM1
might have the potential to modulate cell growth, apoptosis, and heart development.
...
PMID:LYRM1, a gene that promotes proliferation and inhibits apoptosis during heart development. 2093 7
To explore the effects of
LYRM1
knockdown on proliferation, apoptosis, differentiation and mitochondrial function in the embryonic carcinoma (P19) cell model of cardiac differentiation. Knockdown of
LYRM1
using small interfering RNA (siRNA) was confirmed by quantitative real-time PCR. Cell Counting Kit-8(CCK-8) proliferation assays and cell cycle analysis demonstrated that
LYRM1
gene silencing significantly inhibited P19 cell proliferation. Flow cytometry and measurement of their
caspase-3
activities revealed that knockdown of
LYRM1
increased P19 cell apoptosis. Observation of morphological changes using an inverted microscope and expression analysis of specific differentiation marker genes using quantitative real-time PCR and Western blotting revealed that knockdown of
LYRM1
significantly inhibited the differentiation of P19 cells into cardiomyocytes. Furthermore, real-time quantitative PCR applied to detect mitochondrial DNA (mtDNA) copy number implied that there was no significant difference in the
LYRM1
knockdown group compared with the control group. Cellular ATP production investigated by luciferase-based luminescence assay was dramatically decreased in differentiated cells transfected with
LYRM1
RNAi. Fluorescence microscopy and flow cytometery were used to detect the reactive oxygen species (ROS) and the mitochondrial membrane potential (MMP) showed that the level of ROS was dramatically increased and MMP was obviously decreased in differentiated cells transfected with
LYRM1
RNAi. Collectively, knockdown of
LYRM1
promoted apoptosis and suppressed proliferation and differentiation in P19 cells. In addition, knockdown of
LYRM1
induced mitochondrial impairment in P19 cells during differentiation, which was reflected by decreased ATP synthesis, lower MMP and increased ROS levels.
...
PMID:Effect of LYRM1 knockdown on proliferation, apoptosis, differentiation and mitochondrial function in the P19 cell model of cardiac differentiation in vitro. 2675 27